AI biotech Owkin has appointed Andreas Emmenegger, a senior leader with three decades of experience in biotech and finance, as its first Chief Financial Officer.
Andreas will manage investor relations, fundraising and financial strategy at Owkin, supporting its mission of using AI to find the right treatment for every patient.
Andreas has more than 20 years of experience as the CFO of public and private multinational companies, including 15 years in the biotech industry. Andreas was CFO of Swiss biopharma company Molecular Partners from 2007 to 2022, where he led the capital raising in private and public equity and IPOs on the SIX Swiss Exchange in 2014 and on the Nasdaq in 2021. Prior to this, he was CFO of Glycart Biotechnology AG, Head of Strategic Alliance Finance (Genentech) for Roche. Since 2016, Andreas has been a member of the board of directors of the Luzerner Kantonalbank, a publicly listed Swiss bank.
Thomas Clozel, Co-founder and CEO of Owkin, said:
“I am excited to work with Andreas to further unleash the power of Owkin’s world-leading AI and data expertise to benefit patients and doctors. His decades of experience at the top of biotech and finance will help us to achieve our mission of finding the right treatment for every patient.”
Andreas Emmenegger, Chief Financial Officer at Owkin, said:
“I am thrilled to join Owkin's leadership team and to contribute to building the world's premier AI biotech. I am impressed by their unrivalled power of collective intelligence with its innovative de-centralized data infrastructure that has the potential to revolutionize drug development in terms of speed, costs and, most importantly, patient benefit.
“Together with the Owkin Team, I look forward to helping the company create long term value for investors, healthcare providers and patients, always true to its culture and mission.”
Owkin is an AI biotechnology company that uses AI to find the right treatment for every patient. We combine the best of human and artificial intelligence to answer the research questions shared by biopharma and academic researchers. By closing the translational gap between complex biology and new treatments, we bring new diagnostics and drugs to patients sooner.
We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools. Using federated learning, a pioneering collaborative AI framework, Owkin enables partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data.
Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).